Search results
Results From The WOW.Com Content Network
Ocular ischemic syndrome is the constellation of ocular signs and symptoms secondary to severe, chronic arterial hypoperfusion to the eye. [1] Amaurosis fugax is a form of acute vision loss caused by reduced blood flow to the eye; it may be a warning sign of an impending stroke, as both stroke and retinal artery occlusion can be caused by thromboembolism due to atherosclerosis elsewhere in the ...
The ischemic retina releases a variety of factors, the most important of which is vascular endothelial growth factor (VEGF). These factors stimulate the formation of new blood vessels (angiogenesis). These new vessels do not have the same characteristics as the blood vessels originally formed in the eye.
The name non-arteritic anterior ischemic optic neuropathy is derived from several medical terms that describe the condition: [3] Non-arteritic: Indicates that the condition is not related to inflammation or damage of the arteries , which would be arteritic anterior ischemic optic neuropathy .
Arteritic anterior ischemic optic neuropathy (arteritic AION, A-AION or AAION) is vision loss that occurs in giant cell arteritis (also known as temporal arteritis). Temporal arteritis is an inflammatory disease of medium-sized blood vessels that happens especially with advancing age.
Ischemic optic neuropathy (ION) is the loss of structure and function of a portion of the optic nerve due to obstruction of blood flow to the nerve (i.e. ischemia).Ischemic forms of optic neuropathy are typically classified as either anterior ischemic optic neuropathy or posterior ischemic optic neuropathy according to the part of the optic nerve that is affected.
Posterior ischemic optic neuropathy is a syndrome of sudden visual loss with optic neuropathy without initial disc swelling with subsequent development of optic atrophy. This can occur in patients who are predisposed to AAION and NAION as described above as well as those who had cardiac and spine surgery or serious episodes of hypotension.
A systematic review studied the effectiveness of the anti-VEGF drugs ranibizumab and pagatanib sodium for patients with non-ischemic CRVO. [5] Though there was a limited sample size, participants in both treatment groups showed improved visual acuity over 6 month periods, with no safety concerns.
There is no pain. Within approximately six months following the infarct, visual acuity improves by three or more lines of vision on the Snellen Chart (the chart with smaller letters on each lower line) in 42.7% of patients, while in 12.4% of patients, vision worsens by three lines.